The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial
Open accessAbstract
Importance: This analysis provides long-term follow-up in patients with BRAF wild-type advanced melanoma receiving first-line therapy based on anti-programmed cell death 1 receptor inhibitors. Objective: To compare the 3-year survival with nivolumab vs that with dacarbazine in patients with previously untreated BRAF wild-type advanced melanoma. Design, Setting, and Participants: This follow-up of a randomized phase 3 trial analyzed 3-year overall survival data from the randomized, controlled, double-blind CheckMate 066 phase 3 clinical trial. For this ongoing, multicenter academic institution trial, patients were enrolled from January 2013 through February 2014. Eligible patients were 18 years or older with confirmed unresectable previously untreated stage III or IV melanoma and an Eastern Cooperative Oncology Group performance status of 0 or 1 but without a BRAF mutation. Interventions: Patients were treated until progression or unacceptable toxic events with nivolumab (3 mg/kg every 2 weeks plus dacarbazine-matched placebo every 3 weeks) or dacarbazine (1000 mg/m2 every 3 weeks plus nivolumab-matched placebo every 2 weeks). Main Outcome and Measure: Overall survival. Results: At minimum follow-ups of 38.4 months among 210 participants in the nivolumab group (median age, 64 years [range, 18-86 years]; 57.6% male) and 38.5 months among 208 participants in the dacarbazine group (median age, 66 years [range, 25-87 years]; 60.1% male), 3-year overall survival rates were 51.2% (95% CI, 44.1%-57.9%) and 21.6% (95% CI, 16.1%-27.6%), respectively. The median overall survival was 37.5 months (95% CI, 25.5 months-not reached) in the nivolumab group and 11.2 months (95% CI, 9.6-13.0 months) in the dacarbazine group (hazard ratio, 0.46; 95% CI, 0.36-0.59; P < .001). Complete and partial responses, respectively, were reported for 19.0% (40 of 210) and 23.8% (50 of 210) of patients in the nivolumab group compared with 1.4% (3 of 208) and 13.0% (27 of 208) of patients in the dacarbazine group. Additional analyses were performed on outcomes with subsequent therapies. Treatment-related grade 3/4 adverse events occurred in 15.0% (31 of 206) of nivolumab-treated patients and in 17.6% (36 of 205) of dacarbazine-treated patients. There were no deaths due to study drug toxic effects. Conclusions and Relevance: Nivolumab led to improved 3-year overall survival vs dacarbazine in patients with previously untreated BRAF wild-type advanced melanoma. Trial Registration: ClinicalTrials.gov identifier: NCT01721772.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,825
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationOverall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Self-citationNivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Self-citation
Cited by
Sorted by citations
Items 301–352 of 352
Novel biomarkers for melanoma immunotherapy
Wong, N. M. A. (2020) · Minerva Access (University of Melbourne)
Microbiota modulation to fight cancer
Baruch, E. N. (2021) · Science · doi:10.1126/science.abi9360
Creemers, J. H. A., Ankan, A., Roes, K. C. B., Schröder, G., Mehra, N., Figdor, C. G., de Vries, I. J. M., & Textor, J. C. (2021) · medRxiv · doi:10.1101/2021.09.09.21263319
Checkpoint Inhibitors in the Treatment of Metastatic Melanoma
Weppler, A. M., Lau, P. K. H., & McArthur, G. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-05070-2_39
Covelli, A. M., Min, H., McCready, D. R., Hong, N. J. L., Lipa, J. E., Petrella, T. M., & Wright, F. C. (2020) · Springer eBooks · doi:10.1007/978-3-030-48363-0_16
Die Systemtherapie des malignen Melanoms
Ritter, N., Peeken, L., Schultz, E. S., & Debus, D. (2022) · Aktuelle Dermatologie · doi:10.1055/a-1700-9298
Nakamura, Y., Namikawa, K., Kiniwa, Y., Kato, H., Yamasaki, O., Yoshikawa, S., Maekawa, T., Matsushita, S., Takenouchi, T., Inozume, T., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4090733
Peeken, L., Schultz, E. S., & Debus, D. (2021) · Im Focus Onkologie · doi:10.1007/s15015-020-3353-7
The Challenges of Novel Therapies in the Care of the Critically Ill Cancer Patient
Wigmore, T., & Ward, P. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-69584-8.00040-2
Almohideb, M. (2022) · Medicine · doi:10.1097/md.0000000000029390
“Evidence on OS was available from 4 studies.[26,33,36,40] Direct comparison between the nivolumab and the combination of nivolumab plus ipilimumab showed no significant difference in 1-year OS (HR 1.”
BackgroundResultInfluentialSerra‐García, L., Radonich, J., Martí‐Martí, I., Vilana, R., Ripoll, E., Sánchez, M., Alós, L., Carrera, C., Puig, S., Malvehy, J., et al. (2022) · Acta Dermato Venereologica · doi:10.2340/actadv.v102.3981
“This may lead to earlier treatment with less tumoural burden, potentially leading to an improved overall survival rate in these patients (6).”
BackgroundNovel Treatment Strategies for Malignant Anterior Segment Tumors
Kim, J. S.-Y., Chang, E., & Demirci, H. (2022) · Springer eBooks · doi:10.1007/978-3-031-08250-4_30
Melanome der Haut und Schleimhaut
Schilling, B., & Gesierich, A. (2022) · Springer eBooks · doi:10.1007/978-3-662-62808-9_8
Melanoma and immunotherapy: the experience of Sapienza University of Rome
Bottoni, U., Clerico, R., Richetta, A. G., Panasiti, V., Corsetti, P., Roberti, V., Paolino, G., Moliterni, E., Grassi, S., & Calvieri, S. (2023) · Italian Journal of Dermatology and Venereology · doi:10.23736/s2784-8671.23.07424-8
Dabrafenib plus trametinib versus nivolumab for advanced melanoma
Lahoz, D., Reyes-Cosmelli, F., & Quirland, C. (2023) · Medwave · doi:10.5867/medwave.2023.01.2666
Gut microbiota analysis and faecal transplantation to improve surgical outcomes
Cunningham, A., & Harris, D. A. (2023) · British journal of surgery · doi:10.1093/bjs/znad102
Prod’homme, C., Macaire, C., Chevalier, L., Templier, C., & Mortier, L. (2023) · Bulletin du Cancer · doi:10.1016/j.bulcan.2023.04.015
Self-citationEfficacy of Immune Checkpoint Inhibitors in Treating Patients with Melanoma
马, 玉. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1371638
Kalantari, F., Schweighofer-Zwink, G., Rendl, G., Pirich, C., & Beheshti, M. (2023) · The Egyptian Journal of Radiology and Nuclear Medicine · doi:10.1186/s43055-023-01107-9
Die Prognose des Melanoms im Kopf‐Hals‐Bereich im Stadium II hängt vom histologischen Subtyp ab
Jasper, S., Keim, U., Leiter, U., Amaral, T. M. S., Flatz, L., & Forschner, A. (2023) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.15164_g
The role of immunotherapy in the treatment of skin melanoma: a contemporary perspective
Masaeva, P. S. (2024) · Research and Practical Medicine Journal · doi:10.17709/2410-1893-2024-11-2-7 · Cited by 1
Reverse Selection Designs for Accommodating Multiple Control Arms
Samorodnitsky, S., Othus, M. K. D., LeBlanc, M. L., & Wu, M. C. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1282
Díez, B. G., & Segura, P. P. (2025) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2025.01.001
Hinnen, C., Tijssens, F., von Haeseler, E. F., van de Berg, S., & Kapiteijn, E. (2025) · Melanoma Research · doi:10.1097/cmr.0000000000001035
Mao, M., Wang, C., Yang, W., & Liu, B. (2025) · Research Square · doi:10.21203/rs.3.rs-6530143/v1
Wang, Y., Wang, Y., Yang, Y., & Leng, L. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102262
Sreeram, A., Postow, M. A., Moy, A. P., Ariyan, C. E., & Bello, D. M. (2025) · Melanoma Research · doi:10.1097/cmr.0000000000001072
Checkpoint Inhibitors and Beyond: A Systematic Review of Immunotherapy in Cutaneous Malignancies
Rashid, Y. W., Kartika Devi, S., Gonzalez-Espinosa, T. F., Jain, J., Dalain, M., Baig, R., D'Amico, G. A., Mowo-wale, A. G., Khomchenko, M., Baby, N. S., et al. (2025) · Cureus · doi:10.7759/cureus.98959
“A study by Ascierto et al. 2019 showed a remarkable 40% response rate and a median PFS of 5.1 months with nivolumab, which was better than conventional chemotherapy [18].”
InfluentialFerdinandus, J., Zaremba, A., Zimmer, L., Umutlu, L., Seifert, R., Barbato, F., Ugurel, S., Chorti, E., Grünwald, V., Herrmann, K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19128719
Self-citationFerdinandus, J., Zaremba, A., Zimmer, L., Umutlu, L., Seifert, R., Barbato, F., Ugurel, S., Chorti, E., Grünwald, V., Herrmann, K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19128716
Self-citationVisconti, A., Rossi, N., Deriš, H., Lee, K. A., Hanić, M., Trbojević‐Akmačić, I., Thomas, A. M., Bolte, L. A., Björk, J. R., Hooiveld-Noeken, J. S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22613741
Ferdinandus, J., Zaremba, A., Zimmer, L., Umutlu, L., Seifert, R., Barbato, F., Ugurel, S., Chorti, E., Grünwald, V., Herrmann, K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19128713
Self-citationFerdinandus, J., Zaremba, A., Zimmer, L., Umutlu, L., Seifert, R., Barbato, F., Ugurel, S., Chorti, E., Grünwald, V., Herrmann, K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19128725
Self-citationFerdinandus, J., Zaremba, A., Zimmer, L., Umutlu, L., Seifert, R., Barbato, F., Ugurel, S., Chorti, E., Grünwald, V., Herrmann, K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19128728
Self-citationFerdinandus, J., Zaremba, A., Zimmer, L., Umutlu, L., Seifert, R., Barbato, F., Ugurel, S., Chorti, E., Grünwald, V., Herrmann, K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19128722
Self-citationRebecca, V. W., Xiao, M., Kossenkov, A. V., Godok, T., Brown, G. S., Fingerman, D., Alicea, G. M., Wei, M., Ji, H., Portuallo, M. E., et al. (2026) · iScience · doi:10.1016/j.isci.2026.114669 · Cited by 5
Reagan, A. M., McDonald, H. G., Kang, J., Esfahani, H. S., Wright, C. G., Bailey, C. J., Ellis, C. S., Collette, K. R., Patel, R. A., Murillo, M., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1675133
Lima, H. R., Vaz, M. V., Badin, R. C., da Costa, R. S., & Manaças, L. R. A. (2026) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552251410864
Shen, F., Wu, Y., Li, T., Li, Q., Lin, Y., Zheng, G., Zhang, Z. G., Yin, Y., Fang, Y., & Shen, J. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2026.124062 · Cited by 1
Avances en medicina traslacional para el manejo del melanoma: Una revisión narrativa
Arenas-Sánchez, K. A., Perdomo-Farelo, L. D., Mera, A. T., Gómez-Gallego, A. M., Vieira-Rios, S. M., Solarte-Encarnación, A., & Serna-Trejos, J. S. (2025) · Health Care & Global Health · doi:10.22258/hgh.2025.92.213
Brage, S. E., Svedman, F. C., Bergqvist, M., & Helgadóttir, H. (2026) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2026.101595
“1,2 Despite this success, there are still many patients who do not benefit from this treatment, and an accurate and reliable method of identifying likely responders remains elusive.”
Fall, M., Aïdara, S., Diop, M., Kermele, M. A., Seye, M. M., Faye, D., & Dièye, A. M. (2026) · Journal of Phytomolecules and Pharmacology · doi:10.56717/jpp.2026.v05i01.049
Identification et modulation des voies moléculaires impliquées dans l’agressivité du mélanome cutané
Gautron, A. (2019) · theses.fr (ABES) · doi:10.70675/b9c75939z7407z49abzafcbze6e92703d459
Pharmacocinétique / pharmacodynamie du dabrafenib et du trametinib dans les tumeurs solides
Balakirouchenane, D. (2023) · theses.fr (ABES) · doi:10.70675/59ba7d0fz7679z4b46z978ez24aeae7f339c
Radiothérapie interne du mélanome métastatique pigmenté : mécanismes et associations
Rouanet, J. (2019) · theses.fr (ABES) · doi:10.70675/c28349fdz1635z480bzb4e7za5f431ee26c8
Rojas, C., Mortier, L., Park, J., Matamala, L., Baakili, A., Rao, S., Xu, J., Andrieu, L., Wang, R., Wang, H., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014347
Self-citationAteş, Ü. C., & Sarı, F. (2026) · Akdeniz Medical Journal · doi:10.53394/akd.1795129
Jaffee, E. M., & Yap, T. A. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-26-01367
Zhou, Y., He, Y., & Tan, X. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1967814
Postow, M. A., Palaia, J., Burgos, G., DeCongelio, M., Pittman, Z., Paudel, N., Honomichl, R. D., Modi, K., Patel, D. J., Deighton, D. C., et al. (2026) · MDM Policy & Practice · doi:10.1177/23814683261493173
Metadata
- Authors
- Ascierto, P. A., Long, G. V., Robert, C., Brady, B., Dutriaux, C., Di Giacomo, A. M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., Savage, K. J., Hernberg, M. M., Lebbé, C., Charles, J., Mihalcioiu, C., Chiarion-Sileni, V., Mauch, C., Cognetti, F., Ny, L., Arance, A., Svane, I. M., Schadendorf, D., Gogas, H., Saci, A., Jiang, J., Rizzo, J., & Atkinson, V.
- Affiliations
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- The University of Sydney (AU)
- Institut Gustave Roussy (FR)
- Cabrini Hospital (AU)
- Université de Bordeaux (FR)
- UOC Oncological Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
- Inserm (FR)
- Heidelberg University (DE)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- Royal Prince Alfred Hospital (AU)
- Polish Mother’s Memorial Hospital Research Institute, Lodz, Poland
- BC Cancer Agency (CA)
- Helsinki University Hospital (FI)
- Assistance Publique–Hôpitaux de Paris Dermatology and Centre d’Investigation Clinique, University Paris Diderot INSERM U976, Saint Louis Hospital, Paris, France
- Centre National de la Recherche Scientifique (FR)
- McGill University (CA)
- Melanoma Cancer Unit, Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy
- University Hospital Cologne (DE)
- Instituto Nazionale Tumori Regina Elena (IT)
- Sahlgrenska University Hospital (SE)
- Hospital Clínic de Barcelona (ES)
- Herlev Hospital (DK)
- Essen University Hospital (DE)
- National and Kapodistrian University of Athens (GR)
- Bristol-Myers Squibb (United States) (US)
- The University of Queensland (AU)
- Corresponding author
- Ascierto, Paolo A.
- ORCID
- Ascierto, Paolo A.
- Long, Georgina V.
- Robert, Caroline
- Dutriaux, Caroline
- Mortier, Laurent
- Hassel, Jessica C.
- Rutkowski, Piotr
- McNeil, Catriona
- Savage, Kerry J.
- Hernberg, Micaela M.
- Charles, Julie
- Mihalcioiu, Catalin
- Mauch, Cornelia
- Cognetti, Francesco
- Ny, Lars
- Arance, Ana
- Svane, Inge Marie
- Schadendorf, Dirk
- Gogas, Helen
- Saci, Abdel
- Atkinson, Victoria
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2019-02-01
- Volume
- 5
- Issue
- 2
- Pages
- 187
- ISSN
- 2374-2437 (ISSN-L)
- PMC
- PMC6439558
- OpenAlex
- W2898510820
- Cited by
- 352
- References
- 20
- Citations by year
- 2026: 18 · 2025: 26 · 2024: 31 · 2023: 46 · 2022: 47 · 2021: 65 · 2020: 83 · 2019: 33
- FWCI
- 17.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA Oncology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- BRAF wild-type melanoma, advanced melanoma, nivolumab, dacarbazine, immune checkpoint inhibitors, PD-1 inhibitors, first-line therapy, overall survival, long-term follow-up, complete response, partial response, treatment-related adverse events, immunotherapy, progression-free survival, treatment discontinuation
- MeSH terms
- Antineoplastic Agents, Immunological, Nivolumab, Adolescent, Adult, Aged, Aged, 80 and over, Dacarbazine, Double-Blind Method, Female, Humans, Male, Melanoma, Middle Aged, Skin Neoplasms, Time Factors, Treatment Outcome, Disease Progression, Antineoplastic Agents, Alkylating, Proto-Oncogene Proteins B-raf, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
